drugset / Trial / NCT03991819
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug called binimetinib with pembrolizumab is beneficial in people who have advanced non-small cell lung cancer. This study may also see if the combination is safe and may also find the best dose of binimetinib that should be added to pembrolizumab.
Timeline
- Start
- 2019-09-20
- Primary completion
- 2026-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | 30 mg | Oral |
| Subject | Binimetinib | Small molecule | 45 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |